A series of cardiometabolic-related news items has been observed from Dexcom, Lilly/CVS Caremark, Tidepool, Samsung, and the French Ministry of Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Abbott, Kailera Therapeutics, MiniMed, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from FDA, AstraZeneca, Dexcom, and EMA. Below, FENIX provides highlights and insights for the respective news items.
Dexcom hosted its 2026 Investor Day and provided updates across its diabetes business, including the ongoing launch of the G7 15-day, its next-gen G8 CGM, as well as a new dual glucose-potassium sensor (view slides). Following the call, Dexcom’s stock is up ~6% today. In conjunction with the Investor Day, Dexcom also announced updates to its governance structure, including the planned addition of two new independent board members (view press release). Below are highlights and insights from the investor event.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Fractyl Health, and Roche. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Arrowhead, Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Amgen, Dexcom, Zealand Pharma, Esperion Therapeutics, Senseonics, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Ascletis Pharma, GSK, Tandem Diabetes, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Regeneron, Arrowhead Pharmaceuticals, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.